Company / Current Liabilities
Ensysce Biosciences, Inc. Current Liabilities History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$4.6M
FY2025
5-year range
$2.2M / $9.5M
FY2022-FY2025
Trend
+106.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Liabilities returned to growth in FY2025 after 2 years of decline, reaching $5M.
Based on SEC 10-K filings.
$5M in FY2025 with a 3-year CAGR of -21.6%.
Increased from $3M to $5M over the past 2 years.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- -21.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -21.6%, indicating a declining trend.
- In FY2025, current liabilities increased 106.9% year-over-year.
Company context
Key Data Points
- Altman Z-Score -1.53 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.6M | +106.9% |
| FY2024 | $2.2M | -33.8% |
| FY2023 | $3.3M | -64.8% |
| FY2022 | $9.5M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026